EUCTR2017-002753-11-FI进行中（未招募）1 期
The effect of tofacitinib on the activity of JAK-STAT pathways in patients with rheumatoid arthritis (RA) - TofaSTAT17
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •RA patients with active RA (DAS28 >3.2) despite treatment with methotrexate and other synthetic disease-modifying anti-rheumatic drugs
- •Synthetic DMARD and prednisolone (0-10 mg/day) treatment allowed during the trial
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 16
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 8
排除标准
- •Prior biologic or JAK inhibitor treatment
- •Patient has contra-indication to tofacitinib treatment
研究者
相似试验
尚未招募
4 期
Trial of oral drug Tofacitinib in juvenile spondyloarthritisCTRI/2022/12/048330Sanjay Gandhi Postgraduate Institute off Medical Sciences
进行中（未招募）
1 期
Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis (JAKUVEITE)Active non-anterior non-infectious uveitisMedDRA version: 22.1Level: LLTClassification code: 10066681Term: Acute uveitis Class: 10015919CTIS2024-513802-77-00Centre Hospitalier Universitaire Rouen33
尚未招募
不适用
Influence of JAK inhibitors on the disease-associated network of intestinal immune cells in ulcerative colitisUlcerative ColitisNL-OMON51787eids Universitair Medisch Centrum70
招募中
4 期
Investigating the role of JAK inhibition in achieving and maintaining disease remission in psoriatic arthritis (PsA).Psoriatic Arthritis2024-511401-40-00UZ Leuven20
进行中（未招募）
1 期
Investigating the role of JAK inhibition in achieving and maintaining disease remission in psoriatic arthritis (PsA).MedDRA version: 21.0Level: LLTClassification code: 10037160Term: Psoriatic arthritis Class: 10028395Psoriatic ArthritisCTIS2024-511401-40-00Z Leuven20